All News
#abs0380 #acr22 @rheumnow OM1 PsA cohort retro: PsA pts w/comorbidities &prior biologic use (both TNFi&SEC) respond well to IXE after 12 mo even w/monotherapy:IXE mono (82% pts) change in CDAI from BL to 6 mo -3.6 points& 12 mo -4.9 pts (statistically significant for both) https://t.co/5dRk86A9Xr
Olga Petryna DrPetryna ( View Tweet)
de Boysson et al. Incidence GCA across France. Variation in SIR from 7 to 12.Increasing east-west gradient @rheumnow #ACR22 Abstr#0475 https://t.co/XDSSrJcMu5 https://t.co/nlJjcPB3zo
Richard Conway RichardPAConway ( View Tweet)
Abs 0373 details SpA-uveitis more severe in pts w/ smoking hx, axial & peripheral involvement, BASDAI >4, +HLA-B27, female sex, ^ CRP, hx of B ocular involvement. #ACR22 @RheumNow https://t.co/Fg0v6NVQcI
Dr. Rachel Tate uptoTate ( View Tweet)
Mudano et al. explore reasons for COVID-19 vaccine hesitancy. For primary vaccination safety concerns most common reason at 52%. For booster, lack of recommendation from physician biggest factor at 39%. @rheumnow #ACR22 Abstr#0083 https://t.co/ISdTmOjIWs https://t.co/Qr47Or2a6v
Richard Conway RichardPAConway ( View Tweet)
Sun et al. 44% improved adherence in people with SLE following a 3.8 minute intervention involving improved communication @rheumnow #ACR22 Abstr#0063 https://t.co/sFU1FzLUfB https://t.co/9AIOijpI0j
Richard Conway RichardPAConway ( View Tweet)
#abst0199 #acr22 @rheumnow phase II study: Izokibep -highly potent IL-17A inhibitor w/small molecular size designed to overcome limitations of monoclonal Abs: dose-dependent improvement in SF36 & PsAID subdomains, notable improvements in sleep, pain& function. Best in enthesitis https://t.co/VSvhr87PK0
Olga Petryna DrPetryna ( View Tweet)
This might be the greatest honor of my career - thanks for including me @ACRheum!!
Serious question and I’m not sure I want to know the answer
Did anyone know the answer?
Would be embarrassing 😂🤣😅😳
#ACR22 #KnowledgeBowl #RheumPix @RheumNow https://t.co/GhjXUgCgye
Mike Putman EBRheum ( View Tweet)
Daikeler et al. No change in incidence permanent vision loss in GCA at 17%. Late presentation (after PVL) and missed diagnosis key areas for improvement. @rheumnow #ACR22 Abstr#0476 https://t.co/CYBHm8CCBv https://t.co/jIvouncdxw
Richard Conway RichardPAConway ( View Tweet)
Don't repeat the ENA test!
Retrospect. study 23,438 ENA testing from 19,603 pts: 10% + (mostly Ro52 Ab), 89% neg. 13.4% had ENA test repeated. 96% stable results w/o change Conclusion: ENA results rarely change or yield new diagnosis of AARD #ACR22 @rheumnow abst#0725
TheDaoIndex KDAO2011 ( View Tweet)
What's the best tx strategy for SLE-induced severe thrombocytopenia?
This 10-yr retro study by Dr. Cime-Ake et al. showed that RTX provided longer relapse-free survival (vs. CYC, p=0.040). No difference between IV or oral GCs and AZA or MMF. #ACR22 @RheumNow ABST#368 https://t.co/nzXZMY09jx
sheila RHEUMarampa ( View Tweet)
Interim RELIANCE registry data of FMF patients treated with Canakinumab shows efficacy and safety of long-term tx including w/ dose adjustments. Abs 0138 #ACR22 @RheumNow https://t.co/ornfXVIw49 https://t.co/eHTIIEhE37
Dr. Rachel Tate uptoTate ( View Tweet)
Khursheed @LatikaGupta_ et al. Gender gap in rheumatology leadership. Improvements over time in ACR and some APLAR countries, but remains hugely imbalanced @rheumnow #ACR22 Abstr#0085 https://t.co/gw4HYaRlIY https://t.co/xueC3cfqyu
Richard Conway RichardPAConway ( View Tweet)
Should you repeat the dsDNA? SMART-SLE study
>3400 SLE pts, > 37,582 visits. Pts with fluctuating + results or persistently + had higher rates of SLE flares HR 1.56 (95% CI 1.3-1.87, p< 0.001). Inc or Dec dsDNA Ab > 2X from last visit can predict flares @rheumnow #ACR22 abst#0327
TheDaoIndex KDAO2011 ( View Tweet)
❤️ Beta Blockers in LV-GCA
📚65 pts LV-GCA
💊 15(23%) on BB, 50(73%) not
🩻 new aortic dilatation on serial imaging in 15 (23%) - ALL in those NOT on beta blocker 💔
More studies needed, but supportive initial data 🔥
@RheumNow #ACR22 Abst#0477
Patricia Harkins DrTrishHarkins ( View Tweet)
#abs0127 #acr22 @rheumnow 59 adults pts from SAPHO-CNO Study (SCS) reported high scores (0.8 or >SD) for pain interference& fatigue domains vs general population. ⬇️ score on PROMIS physical function; 72.9% of subjects had a T-score < 45. https://t.co/5QfwlB98wV
Olga Petryna DrPetryna ( View Tweet)
#ACR22 Abstr#0769 In patients on DMARDs who didnt seroconvert after primary mRNA COVID vac, is switching to vector or booster with mRNA more effective? An RCT (N=46) showed more pts receiving booster mRNA seroconverted (63%) vs vector (18%). Tcell response was similar @RheumNow https://t.co/5GTsdhNUQZ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Barajas-Ochoa et al. Gender representation in editorial boards of rheum journals. Only 28% women editors overall. Clear discrepancies between journals. Well done @ACR_Journals ! @rheumnow #ACR22 Abstr#104 https://t.co/dpElAUSEuS https://t.co/rDAG6HwNf4
Richard Conway RichardPAConway ( View Tweet)
Neural networks help distinguish between inflammatory arthritis, RA vs PsA, based on MRI inflammatory patterns, focusing on regions of clinical relevance. Fascinating use of tech that needs to be further evaluated clinically. Abs 0242 #ACR22 @RheumNow https://t.co/EMJZkFaMwu https://t.co/hNf70PaZX6
Dr. Rachel Tate uptoTate ( View Tweet)
❓Vessel wall MRI superior to TA-US in c-GCA❓
🔥In c-GCA vessel wall MRI examines beyond the temporal arteries -
✅more 🧠 cranial arteries, including occipital arteries and the all important 👁 orbital structures
Abst#0473
#ACR22 @RheumNow @RennieRhee https://t.co/ayuPP5v7Lh
Patricia Harkins DrTrishHarkins ( View Tweet)
Tune in to Twitter, Facebook or LinkedIn daily at 5pm ET! #ACR22 https://t.co/BPlVx0rRCd
Dr. John Cush RheumNow ( View Tweet)